Insulinothérapie basale chez les patients diabétiques de type 2 [Basal insulin therapy in patients with type 2 diabetes]
Fiche du document
2 juin 2021
- doi: 10.53738/REVMED.2021.17.741.1078
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2021.17.741.1078
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34077039
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_52AF0A9A103F2
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
TherapyCiter ce document
Y. Vuignier et al., « Insulinothérapie basale chez les patients diabétiques de type 2 [Basal insulin therapy in patients with type 2 diabetes] », Serveur académique Lausannois, ID : 10.53738/REVMED.2021.17.741.1078
Métriques
Partage / Export
Résumé
Insulin therapy, often initiated after hygiene and dietary measures and non-insulin antidiabetics, is part of the treatment of patients with type 2 diabetes. Fear of injections or hypoglycemia often delays its implementation. However, its introduction is recommended in cases of poorly balanced diabetes despite a well-controlled therapeutic escalation but also in cases of acute imbalance. Introduction of insulin therapy requires patient education and close monitoring by the healthcare team. Type of insulin and its titration reduce the incidence of hypoglycemia in patients at risk. The determination of the fasting glycemic target - relative to HbA1c - for the titration of insulin is important to define for an optimal benefit (prevention of secondary complications)/risk (hypoglycemia, weight gain) balance.